Predict your next investment

Venture Capital
tvm-lifescience.com

See what CB Insights has to offer

Investments

148

Portfolio Exits

49

Funds

12

Partners & Customers

4

About TVM Capital Life Science

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-years of transatlantic investment track record and in excess of US$1.3bn under management. The life science team boasts more than 120 investments and over 90 exits in the last 30 years, including more than 40 initial public offerings on all major U.S. and European stock exchanges, and combines long-standing international investment and company building experience with their track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, with an integrated team of investment professionals. Fund generations III to VI are managed by managing partners, Dr. Helmut M. SchA¼hsler and Dr. Hubert Birner out of the Munich office.

TVM Capital Life Science Headquarter Location

Ottostraße 4

Munich, D-80333,

Germany

+49 (89) 998 992-0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest TVM Capital Life Science News

Egg Medical hatches technology to shield health care workers from radiation

Mar 27, 2022

Egg Medical hatches technology to shield health care workers from radiation The Arden Hills company has landed $13 million in financing. March 27, 2022 — 2:00pm For decades, as cardiac diagnosis and therapies advanced using X-rays and other imaging, a phenomenon called scatter radiation loomed as a threat to specialists treating a patient. During an X-ray, radiation reflects off a patient and scatters to anyone else in the room. Now a Twin Cities medtech startup, Egg Medical Inc., is building up sales of a new product that's overlaid on an exam table to shield health care professionals from scatter radiation. "Up until now there hasn't been a good solution for the problem," said Bob Wilson, CEO of the Arden Hills-based company. Typically, doctors and radiologists wear heavy lead aprons to protect themselves from radiation. Called an EggNest, the company's product is a carbon-fiber shell goes around the mattress and below and above the table. The shields are a composite of polymer and other materials. The company's testing of the product shows a 91% reduction in scatter radiation. Wilson said that it's meant to protect everyone in the room without interrupting the work flow. Egg Medical was started in 2014 by two interventional cardiologists and one engineer. Wilson, one of the cardiologists, has two previous startups under his belt: Eden Prairie-based Acist Medical Systems and Maple Grove-based HLT Medical. Both of those companies were acquired by Bracco Group, based in Italy. Earlier this month, Egg Medical secured $13 million in financing led by TVM Capital Life Science, a transatlantic venture capital firm. The TVM Capital Group is based in Munich; TVM Capital Life Science operates out of Montreal. Wilson said that the company has now raised approximately $17 million since its inception. Luc Marengère, managing partner of TVM Capital Life Science, said while this marks the company's first investment in Minnesota, the firm already has local connections. "We have a number of high-profile investors in our fund that are based in Minneapolis," said Marengère. TVM is investing $12 million in Egg Medical, said Marengère. He is one of two TVM leaders who are now joining the Egg Medical board of directors. "The product is super differentiated. It's going to make a real difference for the health care professionals that work in cath labs," said Marengère. Wilson said that the company and TVM unexpectedly came together through a "shirt-tail connection" which turned out to be a good fit for both. "A lot of things are chance in life," said Wilson. The EggNest system lists for $59,000, and there are discounts for volume purchases, Wilson said. The company has sold and installed 35 EggNest systems. Egg Medical first started trying to sell the product in late 2019, just before the pandemic hit. Executives shifted to virtual sales pitches after coronavirus spread, the economy went into lockdown and hospitals eliminated most non-emergency procedures. "We probably did 100 Zoom demos," said Wilson. Doctors and radiologists, he added, "weren't doing cardiovascular procedures so everybody had a lot of time." Unlike most medtech companies, Egg Medical did not need FDA approval for its product. An extensive survey about radiation exposure, published in the American Journal of Roentgenology in 2017, determined that the two biggest risks were cataracts and hair loss. Cancer was a concern in the past when the risks of radiation were less well known. But the AJR article noted: "There is no credible evidence of an increased risk of cancer among radiologists who have been practicing during the past 30 or 40 years." Dr. Nicholas Burke, a local cardiologist, said that he started using an EggNest in one lab more than a year ago. Burke works with both Abbott Northwestern Hospital in Minneapolis and the Ridgeview Medical Center in Waconia. "We redid the lab out there [in Ridgeview] and I said, 'I want the EggNest installed in the new lab'," said Burke. Burke had professional connections to Wilson through the University of Minnesota, where Wilson had long been a professor. "The scientific studies that have been done demonstrate a dramatic decrease in radiation exposure for people who are working in the cath lab — the doctors, the techs and nurses," said Burke. "That's why I'm a fan." Burl Gilyard is the Star Tribune's medtech reporter.

TVM Capital Life Science Investments

148 Investments

TVM Capital Life Science has made 148 investments. Their latest investment was in EGG Medical as part of their Series A on February 2, 2022.

CBI Logo

TVM Capital Life Science Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/28/2022

Series A

EGG Medical

$13M

Yes

Undisclosed Investors

8

2/1/2022

PIPE

Centogene

$17M

No

2

3/3/2021

Series B

Access Vascular

$20M

Yes

Undisclosed Investors

12

2/17/2021

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

2/17/2021

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/28/2022

2/1/2022

3/3/2021

2/17/2021

2/17/2021

Round

Series A

PIPE

Series B

Unattributed VC

Unattributed VC

Company

EGG Medical

Centogene

Access Vascular

Subscribe to see more

Subscribe to see more

Amount

$13M

$17M

$20M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Undisclosed Investors

Undisclosed Investors

Sources

8

2

12

10

10

TVM Capital Life Science Portfolio Exits

49 Portfolio Exits

TVM Capital Life Science has 49 portfolio exits. Their latest portfolio exit was Rapid Micro Biosystems on July 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/16/2021

IPO

$99M

4

7/30/2020

Reverse Merger

3

11/7/2019

IPO

$99M

3

5/14/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/13/2018

Acquired

Subscribe to see more

Subscribe to see more

10

Date

7/16/2021

7/30/2020

11/7/2019

5/14/2018

4/13/2018

Exit

IPO

Reverse Merger

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

3

3

10

10

TVM Capital Life Science Acquisitions

2 Acquisitions

TVM Capital Life Science acquired 2 companies. Their latest acquisition was Aspen Technology on October 25, 1994.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/25/1994

Growth Equity

$99M

$4M

IPO

1

5/27/1993

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/1994

5/27/1993

Investment Stage

Growth Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$4M

Note

IPO

Subscribe to see more

Sources

1

10

TVM Capital Life Science Fund History

12 Fund Histories

TVM Capital Life Science has 12 funds, including TVM Life Science Innovation II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/28/2020

TVM Life Science Innovation II

$478M

2

10/14/2020

TVM Life Science Ventures VIII

$368.95M

2

4/13/2015

China BioPharma Capital I

$50M

1

10/6/2014

TVM Life Science Ventures VlI

Subscribe to see more

Subscribe to see more

$99M

10

9/30/2005

TVM Life Science Ventures VI

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/28/2020

10/14/2020

4/13/2015

10/6/2014

9/30/2005

Fund

TVM Life Science Innovation II

TVM Life Science Ventures VIII

China BioPharma Capital I

TVM Life Science Ventures VlI

TVM Life Science Ventures VI

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$478M

$368.95M

$50M

$99M

$99M

Sources

2

2

1

10

10

TVM Capital Life Science Partners & Customers

4 Partners and customers

TVM Capital Life Science has 4 strategic partners and customers. TVM Capital Life Science recently partnered with Eli Lilly and Company, and Neurimmune on October 10, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

10/16/2019

Partner

United States, and Switzerland

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS

He added : `` We highly value our unique partnership with TVM Capital Life Science and Eli Lilly 's Chorus .

2

12/7/2016

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

Partner

South Korea

Subscribe to see more

Subscribe to see more

10

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/16/2019

12/7/2016

Type

Partner

Partner

Partner

Partner

Business Partner

Country

United States, and Switzerland

Switzerland

South Korea

United States

News Snippet

Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS

He added : `` We highly value our unique partnership with TVM Capital Life Science and Eli Lilly 's Chorus .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

TVM Capital Life Science Team

22 Team Members

TVM Capital Life Science has 22 team members, including current Chief Financial Officer, Stefan Fischer.

Name

Work History

Title

Status

Stefan Fischer

Chief Financial Officer

Current

Rolf Starck

Controller

Current

Hubert Birner

Managing Partner

Current

Luc Marengere

Managing Partner

Current

Sascha Berger

General Partner

Current

Name

Stefan Fischer

Rolf Starck

Hubert Birner

Luc Marengere

Sascha Berger

Work History

Title

Chief Financial Officer

Controller

Managing Partner

Managing Partner

General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.